Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 90

1.

Erratum: Will PI3K pathway inhibitors be effective as single agents in patients with cancer?

Garrett JT, Chakrabarty A, Arteaga CL.

Oncotarget. 2018 Aug 17;9(64):32400. doi: 10.18632/oncotarget.26017. eCollection 2018 Aug 17.

2.

Erratum.

[No authors listed]

Sci Technol Adv Mater. 2016 Apr 19;17(1):188. eCollection 2016.

3.

Erratum: Functional analysis of MKP-1 and MKP-2 in breast cancer tamoxifen sensitivity.

Haagenson KK, Zhang JW, Xu Z, Shekhar MPV, Wu GS.

Oncotarget. 2018 Oct 16;9(81):35286. doi: 10.18632/oncotarget.26258. eCollection 2018 Oct 16.

4.

Erratum: Drug Discovery Approaches to Target Wnt Signaling in Cancer Stem Cells.

Curtin JC, Lorenzi MV.

Oncotarget. 2018 Oct 5;9(78):34856. doi: 10.18632/oncotarget.26220. eCollection 2018 Oct 5.

5.

Erratum: Ocular toxicities associated with targeted anticancer agents: an analysis of clinical data with management suggestions.

Fu C, Gombos DS, Lee J, George GC, Hess K, Whyte A, Hong DS.

Oncotarget. 2019 Jan 29;10(9):1011-1013. doi: 10.18632/oncotarget.26658. eCollection 2019 Jan 29.

6.

Erratum: Predicting clinically significant prostate cancer using DCE-MRI habitat descriptors.

Parra NA, Lu H, Li Q, Stoyanova R, Pollack A, Punnen S, Choi J, Abdalah M, Lopez C, Gage K, Park JY, Kosj Y, Pow-Sang JM, Gillies RJ, Balagurunathan Y.

Oncotarget. 2019 Mar 12;10(21):2113. doi: 10.18632/oncotarget.26802. eCollection 2019 Mar 12.

7.

Erratum: Targeting Metabolic Remodeling in Glioblastoma Multiforme.

Wolf A, Agnihotri S, Guha A.

Oncotarget. 2018 Oct 5;9(78):34855. doi: 10.18632/oncotarget.26219. eCollection 2018 Oct 5.

8.

Correction: Implications of PI3K/AKT inhibition on REST protein stability and neuroendocrine phenotype acquisition in prostate cancer cells.

Chen R, Li Y, Buttyan R, Dong X.

Oncotarget. 2018 Jul 3;9(51):29842. doi: 10.18632/oncotarget.25759. eCollection 2018 Jul 3.

10.

Erratum: Disruption of Myc-Max Heterodimerization with Improved Cell-Penetrating Analogs of the Small Molecule 10074-G5.

Wang H, Chauhan J, Hu A, Pendleton K, Yap JL, Sabato PE, Jones JW, Perri M, Yu J, Cione E, Kane MA, Fletcher S, Prochownik EV.

Oncotarget. 2018 Oct 12;9(80):35196. doi: 10.18632/oncotarget.26241. eCollection 2018 Oct 12.

11.

Erratum: Up-regulation of LINC00161 correlates with tumor migration and invasion and poor prognosis of patients with hepatocellular carcinoma.

Xu LC, Chen QN, Liu XQ, Wang XM, Chang QM, Pan Q, Wang L, Wang YL.

Oncotarget. 2019 Feb 15;10(14):1474. doi: 10.18632/oncotarget.26712. eCollection 2019 Feb 15.

12.

Erratum: Seven papers on fused-ring heterocyclic ketones containing an N-tosyl-pyrrolo-[3,4-c]pyrano moiety. Corrigenda.

Chinnakali K, Jayagobi M, Fun HK.

Acta Crystallogr Sect E Struct Rep Online. 2007 Dec 12;64(Pt 1):e11. doi: 10.1107/S1600536807063817.

13.

Erratum: CRIPTO overexpression promotes mesenchymal differentiation in prostate carcinoma cells through parallel regulation of AKT and FGFR activities.

Terry S, El-Sayed IY, Destouches D, Maillé P, Nicolaiew N, Ploussard G, Semprez F, Pimpie C, Beltran H, Londono-Vallejo A, Allory Y, de la Taille A, Salomon DS, Vacherot F.

Oncotarget. 2019 Jun 25;10(41):4247-4248. doi: 10.18632/oncotarget.27038. eCollection 2019 Jun 25.

14.

Erratum: Molecular profiling of colorectal tumors stratified by the histological tumor-stroma ratio - Increased expression of galectin-1 in tumors with high stromal content.

Sandberg TP, Oosting J, van Pelt GW, Mesker WE, Tollenaar RAEM, Morreau H.

Oncotarget. 2019 Mar 22;10(24):2416. doi: 10.18632/oncotarget.26820. eCollection 2019 Mar 22.

15.

Correction: The dual PI3K/mTOR inhibitor dactolisib elicits anti-tumor activity in vitro and in vivo.

Shi F, Zhang J, Liu H, Wu L, Jiang H, Wu Q, Liu T, Lou M, Wu H.

Oncotarget. 2018 Mar 30;9(24):17255. doi: 10.18632/oncotarget.25063. eCollection 2018 Mar 30.

16.

Correction: Combined inhibition of PI3K and Src kinases demonstrates synergistic therapeutic efficacy in clear-cell renal carcinoma.

Caroline R, Sofia G, Catherine P, Remi B, Pierre C, Olivier B, Laurent G, Valentin A, Claude C, Odile F.

Oncotarget. 2019 Mar 15;10(22):2236. doi: 10.18632/oncotarget.26807. eCollection 2019 Mar 15.

17.

Targeting the phosphoinositide-3 (PI3) kinase pathway in breast cancer.

Baselga J.

Oncologist. 2011;16 Suppl 1:12-9. doi: 10.1634/theoncologist.2011-S1-12. Review.

18.

Correction: Genipin suppresses colorectal cancer cells by inhibiting the Sonic Hedgehog pathway.

Kim BR, Jeong YA, Na YJ, Park SH, Jo MJ, Kim JL, Jeong S, Lee SY, Kim HJ, Oh SC, Lee DH.

Oncotarget. 2018 Jun 19;9(47):28796. doi: 10.18632/oncotarget.25677. eCollection 2018 Jun 19.

19.

Correction: Niclosamide and its analogs are potent inhibitors of Wnt/β-catenin, mTOR and STAT3 signaling in ovarian cancer.

Arend RC, Londoño-Joshi AI, Gangrade A, Katre AA, Kurpad C, Li Y, Samant RS, Li PK, Landen CN, Yang ES, Hidalgo B, Alvarez RD, Straughn JM, Forero A, Buchsbaum DJ.

Oncotarget. 2018 Apr 10;9(27):19459. doi: 10.18632/oncotarget.25151. eCollection 2018 Apr 10.

20.

Erratum.

[No authors listed]

Open Forum Infect Dis. 2015 Mar 12;2(1):ofv041. doi: 10.1093/ofid/ofv041. eCollection 2015 Jan.

Supplemental Content

Support Center